{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:11:11Z","timestamp":1789027871562,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chinese Society of Clinical Oncology Foundation","award":["Y-tongshu2021\/qn-0217"],"award-info":[{"award-number":["Y-tongshu2021\/qn-0217"]}]},{"name":"Chinese Society of Clinical Oncology Foundation","award":["Y-XD202001-0318"],"award-info":[{"award-number":["Y-XD202001-0318"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["817732598"],"award-info":[{"award-number":["817732598"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"crossref","award":["22ZR1438300"],"award-info":[{"award-number":["22ZR1438300"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple primary cancer (MPC) denotes individuals with two or more malignant tumors occurring simultaneously or successively. Herein, a total of 11,000 pancancer patients in TCGA database (1993\u20132013) were divided into MPC or non-MPC groups based on their history of other malignant tumors. The incidence of MPC has risen to 8.5\u201313.1% since 2000. Elderly individuals, males, early-stage cancer patients, and African Americans and Caucasians are identified as independent risk factors (p\u2009&lt;\u20090.0001). Non-MPC patients exhibit significantly longer overall survival (OS) and disease-free survival (DFS) (p\u2009=\u20090.0038 and p\u2009=\u20090.0014). Age (p\u2009&lt;\u20090.001) and tumor staging at initial diagnosis (p\u2009&lt;\u20090.001) contribute to this difference. In our center, MPC was identified in 380 out of 801 tumor events based on SEER criteria. The peak occurrence of secondary primary was about 1\u20135 years after the first primary tumor, with a second small peak around 10\u201315 years. Multiple tumors commonly occur in the same organ (e.g., breast and lung), constituting 12.6%. Certain cancer types, notably skin cutaneous melanoma (SKCM), exhibit significantly higher tumor mutational burden (TMB) in the MPC group (17.31 vs. 6.55 mutations\/MB, p\u2009&lt;\u20090.001), with high TMB associated with improved survival (p\u2009&lt;\u20090.001). High TMB in MPC may serve as a predictor for potential immunotherapy application.<\/jats:p>","DOI":"10.1038\/s41598-024-52659-3","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T09:02:45Z","timestamp":1706518965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A pancancer analysis of the clinical and genomic characteristics of multiple primary cancers"],"prefix":"10.1038","volume":"14","author":[{"given":"Baiwen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojiao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinglei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuiping","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"key":"52659_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000172","volume":"2","author":"A Vogt","year":"2017","unstructured":"Vogt, A. et al. Multiple primary tumours: Challenges and approaches, a review. ESMO Open 2, e000172. https:\/\/doi.org\/10.1136\/esmoopen-2017-000172 (2017).","journal-title":"ESMO Open"},{"key":"52659_CR2","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/1471-2407-14-272","volume":"14","author":"A Coyte","year":"2014","unstructured":"Coyte, A., Morrison, D. S. & McLoone, P. Second primary cancer risk\u2014The impact of applying different definitions of multiple primaries: Results from a retrospective population-based cancer registry study. BMC Cancer 14, 272. https:\/\/doi.org\/10.1186\/1471-2407-14-272 (2014).","journal-title":"BMC Cancer"},{"key":"52659_CR3","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1186\/s12885-021-08766-9","volume":"21","author":"P Tanjak","year":"2021","unstructured":"Tanjak, P. et al. Risks and cancer associations of metachronous and synchronous multiple primary cancers: A 25-year retrospective study. BMC Cancer 21, 1045. https:\/\/doi.org\/10.1186\/s12885-021-08766-9 (2021).","journal-title":"BMC Cancer"},{"key":"52659_CR4","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1002\/cncr.30164","volume":"122","author":"N Donin","year":"2016","unstructured":"Donin, N. et al. Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer 122, 3075\u20133086. https:\/\/doi.org\/10.1002\/cncr.30164 (2016).","journal-title":"Cancer"},{"key":"52659_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12885-020-6584-2","volume":"20","author":"A Feller","year":"2020","unstructured":"Feller, A. et al. Correction to: The relative risk of second primary cancers in Switzerland: A population-based retrospective cohort study. BMC Cancer 20, 87. https:\/\/doi.org\/10.1186\/s12885-020-6584-2 (2020).","journal-title":"BMC Cancer"},{"key":"52659_CR6","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/cas.12433","volume":"105","author":"M Utada","year":"2014","unstructured":"Utada, M., Ohno, Y., Hori, M. & Soda, M. Incidence of multiple primary cancers and interval between first and second primary cancers. Cancer Sci. 105, 890\u2013896. https:\/\/doi.org\/10.1111\/cas.12433 (2014).","journal-title":"Cancer Sci."},{"key":"52659_CR7","unstructured":"Karaholios, E. E. et al. Second Primary Cancers in Victoria (2013)."},{"key":"52659_CR8","volume-title":"SEER Cancer Statistics Review, 1975\u20132005","author":"LAG Ries","year":"2008","unstructured":"Ries, L. A. G. et al. SEER Cancer Statistics Review, 1975\u20132005 (National Cancer Institute, 2008)."},{"key":"52659_CR9","unstructured":"C F: Cancer Facts & Figures 2009. ConcerOrg (2009)."},{"key":"52659_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1634\/theoncologist.12-1-20","volume":"12","author":"MJ Hayat","year":"2007","unstructured":"Hayat, M. J., Howlader, N., Reichman, M. E. & Edwards, B. K. Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology, and end results (SEER) Program. The Oncologist 12, 20\u201337. https:\/\/doi.org\/10.1634\/theoncologist.12-1-20 (2007).","journal-title":"The Oncologist"},{"key":"52659_CR11","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/0002-9343(64)90107-x","volume":"36","author":"KL Melmon","year":"1964","unstructured":"Melmon, K. L. & Rosen, S. W. Lindau\u2019s disease. Review of the literature and study of a large kindred. Am. J. Med. 36, 595\u2013617. https:\/\/doi.org\/10.1016\/0002-9343(64)90107-x (1964).","journal-title":"Am. J. Med."},{"key":"52659_CR12","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1038\/s41588-019-0525-5","volume":"51","author":"O Pich","year":"2019","unstructured":"Pich, O. et al. The mutational footprints of cancer therapies. Nat. Genet. 51, 1732\u20131740. https:\/\/doi.org\/10.1038\/s41588-019-0525-5 (2019).","journal-title":"Nat. Genet."},{"key":"52659_CR13","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/ijc.28988","volume":"135","author":"C Cybulski","year":"2014","unstructured":"Cybulski, C., Nazarali, S. & Narod, S. A. Multiple primary cancers as a guide to heritability. Int. J. Cancer 135, 1756\u20131763. https:\/\/doi.org\/10.1002\/ijc.28988 (2014).","journal-title":"Int. J. Cancer"},{"key":"52659_CR14","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nm1087","volume":"10","author":"B Vogelstein","year":"2004","unstructured":"Vogelstein, B. & Kinzler, K. W. Cancer genes and the pathways they control. Nat. Med. 10, 789\u2013799. https:\/\/doi.org\/10.1038\/nm1087 (2004).","journal-title":"Nat. Med."},{"key":"52659_CR15","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/1078-0432.Ccr-11-2283","volume":"18","author":"MH Tan","year":"2012","unstructured":"Tan, M. H. et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin. Cancer Res. 18, 400\u2013407. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-11-2283 (2012).","journal-title":"Clin. Cancer Res."},{"key":"52659_CR16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.1088759","volume":"302","author":"MC King","year":"2003","unstructured":"King, M. C., Marks, J. H. & Mandell, J. B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302, 643\u2013646. https:\/\/doi.org\/10.1126\/science.1088759 (2003).","journal-title":"Science"},{"key":"52659_CR17","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1177\/2050640620977129","volume":"9","author":"SEM van de Ven","year":"2021","unstructured":"van de Ven, S. E. M. et al. Increased risk of second primary tumours in patients with oesophageal squamous cell carcinoma: A nationwide study in a Western population. United Eur. Gastroenterol. J. 9, 497\u2013506. https:\/\/doi.org\/10.1177\/2050640620977129 (2021).","journal-title":"United Eur. Gastroenterol. J."},{"key":"52659_CR18","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.eururo.2015.06.042","volume":"70","author":"MG Cumberbatch","year":"2016","unstructured":"Cumberbatch, M. G., Rota, M., Catto, J. W. & La Vecchia, C. The role of tobacco smoke in bladder and kidney carcinogenesis: A comparison of exposures and meta-analysis of incidence and mortality risks. Eur. Urol. 70, 458\u2013466. https:\/\/doi.org\/10.1016\/j.eururo.2015.06.042 (2016).","journal-title":"Eur. Urol."},{"key":"52659_CR19","doi-asserted-by":"publisher","first-page":"7480","DOI":"10.3748\/wjg.v20.i23.7480","volume":"20","author":"M \u0141awniczak","year":"2014","unstructured":"\u0141awniczak, M. et al. Synchronous and metachronous neoplasms in gastric cancer patients: A 23-year study. World J. Gastroenterol. 20, 7480\u20137487. https:\/\/doi.org\/10.3748\/wjg.v20.i23.7480 (2014).","journal-title":"World J. Gastroenterol."},{"key":"52659_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/1759-7714.12158","volume":"6","author":"SW Kim","year":"2015","unstructured":"Kim, S. W. et al. Multiple primary cancers involving lung cancer at a single tertiary hospital: Clinical features and prognosis. Thoracic Cancer 6, 159\u2013165. https:\/\/doi.org\/10.1111\/1759-7714.12158 (2015).","journal-title":"Thoracic Cancer"},{"key":"52659_CR21","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","volume":"32","author":"DJ McGrail","year":"2021","unstructured":"McGrail, D. J. et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann. Oncol. 32, 661\u2013672. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.006 (2021).","journal-title":"Ann. Oncol."},{"key":"52659_CR22","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/s1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. The Lancet Oncol. 21, 1353\u20131365. https:\/\/doi.org\/10.1016\/s1470-2045(20)30445-9 (2020).","journal-title":"The Lancet Oncol."},{"key":"52659_CR23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke, J. J., Flaherty, K. T., Ribas, A. & Long, G. V. Targeted agents and immunotherapies: Optimizing outcomes in melanoma. Nat. Rev. Clin. Oncol. 14, 463\u2013482. https:\/\/doi.org\/10.1038\/nrclinonc.2017.43 (2017).","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52659-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52659-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52659-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T13:08:19Z","timestamp":1706792899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52659-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["52659"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-52659-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,29]]},"assertion":[{"value":"14 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2367"}}